Found Review
Semaglutide & tirzepatide GLP-1 weight-loss telehealth · Independently scored 8.8/10
Best for: tirzepatide at $169/month, 37% under the register median
Found's strongest column is the clinical side — which molecules it will prescribe, and how it handles dosing.
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
Not stated
Lab work
Not stated
Coaching
In the price
No insurance needed · Vetted by our editors
Found is a personalized weight care platform. It runs on a self-pay membership, and medication costs sit on top of that.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Found at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide
- Starting price
- $99/mo ($169/mo cash-pay on 12-month prepaid plan, medication+membership+coaching included; promo_price 99 = $99/mo WITH insu...)
- What's included
- Medication · Consult · Coaching
- Availability
- All 50 states
- FDA status
- No FDA warning letter on record
How Found scores
Six columns, each one computed from something Found has published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where it publishes nothing, that absence is what gets scored. Every seller in the register goes through the same six columns.
Value25%
8.3/10$169/month is 37% below the register median of $267 for compounded tirzepatide.
Effectiveness25%
10.0/10Dispenses orforglipron and semaglutide and tirzepatide, including the FDA-approved product. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
8.0/10On the seller's own pages, a price is published before the questionnaire starts.
Trust & Safety15%
8.5/10does not name a dispensing pharmacy; shows a price before asking for health information; publishes its state list. Our verification confidence is high.
Accessibility10%
10.0/10Publishes coverage in 50 of 50 states.
Support10%
7.0/10The price covers medication, consult, coaching.
A seller that will not show a price before an intake loses points on Value and carries that note in its review. Withholding the number is itself a finding. How we score →
What we checked on Found
Last checked July 2026- Re-read the price on file across 7 dose or plan tiers
- Checked state coverage: all 50
- Established what the monthly figure covers, and what it leaves out
- Searched our FDA enforcement register for this operator
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below. Editorial confidence in this data: high.
What signing up with Found involves
Assembled from this seller’s entry in the register — the price record, the state list, the dispensing pharmacy where one is named, and what the monthly figure covers. It describes what a reader can expect to meet on the way to a prescription, and what is missing from the seller’s own disclosures. It is not a clinical judgment and not a prescribing decision.
- 1Found publishes a price on its own site before asking anything about you. You can compare it against this register without starting a questionnaire.
- 2The intake is a written questionnaire. No live video visit or baseline bloodwork is recorded as required.
- 3Found does not say which pharmacy dispenses the medication. That is common here and it means you cannot check the pharmacy's record before you buy.
- 4The monthly price is recorded as covering medication, consult, coaching.
- Cheapest standing monthly prices on record: tirzepatide $169. Membership fees, first-month rates and insured copays are excluded from those figures.
- Coverage is published for all 50 states.
- The medication is compounded, so it is not an FDA-approved product and has not been reviewed by the agency for safety, effectiveness or manufacturing quality.
GLP-1 medications Found offers
Each one has its own guide: how the molecule works, the dosing schedule, the side effects that show up in practice, and what the trials actually measured.
Pricing
Prices re-verified
$169/mo cash-pay on 12-month prepaid plan, medication+membership+coaching included; promo_price 99 = $99/mo WITH insurance (12-mo prepaid). Month-to-month: $199/mo insurance, $289/mo cash. Site-wide '$100 off today' checkout promo running.
Same single Compounded GLP-1 Plan price as semaglutide — no per-drug split published (final drug/price assignment is quiz-gated); $169/mo cash 12-mo prepaid ($289/mo month-to-month cash), $99/mo insurance prepaid.
'Starting cash price ~$149/mo' on /medication/foundayo comparison table; NEW offering since last verification.
Homepage carousel 'Wegovy® from $650/mo+'; but /medication/foundayo table lists 'Wegovy® Pen ... Starting cash price ~$199/mo' — internally inconsistent on their own site.
Homepage carousel 'Zepbound® from $650/mo+'; /medication/foundayo table shows Zepbound ~$299/mo starting cash price.
Homepage carousel 'Ozempic® $1100/mo' — unchanged from prior verification.
Homepage carousel 'Mounjaro® ~$1100/mo' — unchanged. Non-GLP-1 generics plan from $49/mo; microdosing program price not published.
Check the price yourself before you pay
Every figure here was read off Found's own checkout on the date shown. Sellers move prices without announcing it, and promotional rates lapse, so confirm the standing cost on their site before committing.
In its favor
- Tirzepatide at $169 a month, 37% below the $267 median for the same drug and form across this register
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- The monthly figure covers medication, consult, coaching
- Coverage is published for all 50 states
- No FDA warning letter matched this operator when we searched our enforcement register
Against it
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- Its orforglipron and semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
What Found charges
Found charges $149/month. That sits at the affordable end of what we track.
- Compounded semaglutide — $99 first month, then $169/month
- Compounded tirzepatide — $99 first month, then $169/month
- Oral orforglipron (foundayo) — $149/month
- Brand-name semaglutide (wegovy) — $650/month
- Brand-name tirzepatide (zepbound) — $650/month
- Brand-name semaglutide (ozempic) — $1100/month
Across the GLP-1 providers in our register the median standing price is about $169/month, so Found is genuinely under the middle rather than merely advertising that it is.
Gala, at about $149/month, is the closest thing we track to a like-for-like alternative.
What Found dispenses
Found prescribes semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the pair carrying the strongest published outcome data. The choice is between an FDA-approved pen and a compounded preparation that costs less. Compounding is lawful and often appropriate, but a compounded product is not an approved one, and the price gap is largely that difference.
A needle-free oral option is genuinely uncommon and is the reason some readers will look at Found at all. Set expectations on the evidence, though: the published weight-loss trials for these molecules used injections. Oral and sublingual delivery of peptides is far less studied, so treat it as a route that solves the needle problem rather than as a demonstrated equal to the shot.
What we could verify
On the record: it treats patients in all 50 states and coaching is included rather than sold on top. We searched the federal warning-letter record for this operator and came back with nothing. Because the medication is compounded and no dispensing pharmacy is named publicly, the single most useful question to ask at intake is which licensed pharmacy fills the prescription. A seller that will not answer that has told you something. How we weigh oversight, disclosure and price evidence is set out in our scoring methodology.
Who should look elsewhere
- You need to bill insurance. Like most of this market, this is cash-pay.
It fits if
- the lowest standing monthly cost is what you are solving for
- injections are the thing keeping you from starting
- you want coaching bundled rather than metered
- you need access regardless of where you live
Our read
Found competes on price and does it without an obvious sacrifice elsewhere: $149/month, no warning letter on file, and access that is not unusually restricted.
The Bottom Line
Found's strongest column is the clinical side — which molecules it will prescribe, and how it handles dosing.
Before you pay Found
Starting at $149/month. Check today's price, then book the free consultation.
Alternatives to Found
Editorial score · methodology
Editorial score · methodology
Synergy Rx
Best for: knowing which pharmacy fills the vial — it names Belmar Pharmacy
Editorial score · methodology
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
Cited across this Found review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of August 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
See Found's current pricing
Plans start at $149/month. The free consultation is where you learn whether you qualify, and what it costs today.